Skip to main content

Table 2 Positive (complete or partial) and negative (stable disease or progression) RECIST 1.1 responses after melphalan HPP, associated with > 60% (Positive) or < 60% (Negative) melphalan-treated CTC cell death

From: Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study

Chemosensitivity of CTCsRECIST 1.1 responseTotal
Positive (CR + PR)Negative (SD + PD)
Positive (> 60%)123
Negative (≤ 60%)044
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease